Figure 6 From: The protein C pathway: implications for the design of the RESPOND study RESPOND study design. Distribution and outcome of corresponding DrotAA (Xigris®)-treated PROWESS [9] patients. DrotAA, drotrecogin alfa (activated); EOI, end of infusion; LLN, lower limit of normal; PC, protein C; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; RESPOND, Research Evaluating Serial Protein C levels in severe sepsis patients ON Drotrecogin alfa [activated]. †Mortality.Back to article page